Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Net Income (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Net Income data on record, last reported at -$9.2 million in Q3 2025.

  • For Q3 2025, Net Income rose 4.34% year-over-year to -$9.2 million; the TTM value through Sep 2025 reached -$38.5 million, up 5.53%, while the annual FY2024 figure was -$40.2 million, 34.38% up from the prior year.
  • Net Income reached -$9.2 million in Q3 2025 per ASMB's latest filing, up from -$10.2 million in the prior quarter.
  • Across five years, Net Income topped out at -$8.8 million in Q1 2025 and bottomed at -$62.8 million in Q4 2021.
  • Average Net Income over 5 years is -$18.7 million, with a median of -$16.9 million recorded in 2023.
  • Peak YoY movement for Net Income: plummeted 461.45% in 2021, then surged 64.33% in 2022.
  • A 5-year view of Net Income shows it stood at -$62.8 million in 2021, then soared by 64.33% to -$22.4 million in 2022, then skyrocketed by 51.05% to -$11.0 million in 2023, then rose by 5.72% to -$10.3 million in 2024, then grew by 11.02% to -$9.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$9.2 million in Q3 2025, -$10.2 million in Q2 2025, and -$8.8 million in Q1 2025.